Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients

Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients

10.1002/ijc.33822

Saved in:

Bibliographic Details
Main Authors:	Huang, Yiqing, Soon, Yu Yang, Aminkeng, Folefac, Tay, Sen Hee, Ang, Yvonne, Kee, Adrian CL, Goh, Boon Cher, Wong, Alvin SC, Soo, Ross A
Other Authors:	CANCER SCIENCE INSTITUTE OF SINGAPORE
Format:	Article
Language:	English
Published:	WILEY 2022
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology immune checkpoint inhibitors immune-related adverse events nonsmall cell lung cancer CHECKPOINT INHIBITORS CHEMOTHERAPY PEMBROLIZUMAB IPILIMUMAB NIVOLUMAB TOXICITY ASSOCIATION CARBOPLATIN COMBINATION BLOCKADE
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/235038
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Description
Summary:	10.1002/ijc.33822